Risk Factors for Immune Checkpoint Inhibitor Immunotherapy Toxicity Among Older Adults with Cancer

被引:6
|
作者
Johns, Andrew C. [1 ]
Yang, Mike [2 ]
Wei, Lai [3 ]
Grogan, Madison [4 ]
Spakowicz, Daniel [3 ,4 ]
Patel, Sandipkumar H. [4 ]
Li, Mingjia [5 ]
Husain, Marium [4 ]
Kendra, Kari L. [4 ]
Otterson, Gregory A. [4 ]
Rosko, Ashley E. [6 ]
Andersen, Barbara L. [7 ]
Carbone, David P. [4 ]
Owen, Dwight H. [4 ]
Presley, Carolyn J. [4 ,8 ]
机构
[1] Ohio State Univ, Dept Internal Med, Wexner Med Ctr, Columbus, OH 43210 USA
[2] Ohio State Univ, Coll Med, Columbus, OH 43210 USA
[3] Ohio State Univ, Dept Biomed Informat, Columbus, OH 43210 USA
[4] Ohio State Univ, Dept Internal Med, Div Med Oncol, Comprehens Canc Ctr, Columbus, OH 43210 USA
[5] Ohio State Univ, Div Hosp Med, Dept Internal Med, Wexner Med Ctr, Columbus, OH 43210 USA
[6] Ohio State Univ, Dept Internal Med, Div Hematol, Wexner Med Ctr, Columbus, OH 43210 USA
[7] Ohio State Univ, Dept Psychol, Columbus, OH 43210 USA
[8] Ohio State Univ, James Canc Hosp & Solove Res Inst, Comprehens Canc Ctr, 13th Floor Lincoln Tower, 1800 Cannon Dr, Columbus, OH 43210 USA
基金
美国国家卫生研究院;
关键词
checkpoint inhibitor; immunotherapy; toxicity; geriatrics; immune-related adverse events; CHEMOTHERAPY TOXICITY; DEPRESSION; MANAGEMENT; SURVIVAL;
D O I
10.1093/oncolo/oyad097
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Immune checkpoint inhibitor immunotherapy is revolutionizing cancer care but can lead to significant toxicity. This article describes potential risk factors for immune-related adverse events among older adults. Objectives Immune checkpoint inhibitor immunotherapy (IO) is revolutionizing cancer care but can lead to significant toxicity. This study seeks to describe potential risk factors for immune-related adverse events (irAEs) specifically among older adults. Materials and Methods This was a retrospective study at a single academic comprehensive cancer center based on chart review data abstracted by physicians. For patients aged >= 70 years, frequency, type, and grade of irAEs and their association with baseline patient demographics, comorbidities, mobility, and functional status were characterized using bivariate analysis. Based on those results, multivariable logistic regressions were constructed to model the association between these characteristics with any grade and grade 3 or higher irAEs. Results Data were analyzed for 238 patients aged >= 70 years who received IO for mostly (>= 90%) advanced cancer between 2011 and 2018. Thirty-nine percent of older adults experienced an irAE and 13% experienced one that was grade 3 or higher. In the multivariable analysis, depression was associated with an increased incidence of any grade irAE, while decreased life-space mobility was associated with an increased incidence of grade >= 3 irAEs. Conclusion Most characteristics of special interest among older adults, include fall risk, weight loss, cognitive limitations, and hearing loss, were not associated with irAEs in our study. However, decreased life-space mobility and depression are potential risk factors for IO toxicity among older adults with advanced cancer. Interventions designed to evaluate and mitigate modifiable risk factors for treatment-related toxicity are needed, and the results of this study may be useful for guiding those efforts.
引用
收藏
页码:E625 / E632
页数:8
相关论文
共 50 条
  • [1] Checkpoint inhibitor immunotherapy toxicity and overall survival among older adults with advanced cancer
    Johns, Andrew C.
    Wei, Lai
    Grogan, Madison
    Hoyd, Rebecca
    Bridges, John F. P.
    Patel, Sandipkumar H.
    Li, Mingjia
    Husain, Marium
    Kendra, Kari L.
    Otterson, Gregory A.
    Burkart, Jarred T.
    Rosko, Ashley E.
    Andersen, Barbara L.
    Carbone, David P.
    Owen, Dwight H.
    Spakowicz, Daniel J.
    Presley, Carolyn J.
    JOURNAL OF GERIATRIC ONCOLOGY, 2021, 12 (05) : 813 - 819
  • [2] A Review of Cancer Immunotherapy Toxicity: Immune Checkpoint Inhibitors
    Chhabra, Neeraj
    Kennedy, Joseph
    JOURNAL OF MEDICAL TOXICOLOGY, 2021, 17 (04) : 411 - 424
  • [3] A Review of Cancer Immunotherapy Toxicity: Immune Checkpoint Inhibitors
    Neeraj Chhabra
    Joseph Kennedy
    Journal of Medical Toxicology, 2021, 17 : 411 - 424
  • [4] Immune checkpoint inhibitor toxicity and associated outcomes in older patients with cancer
    Hayashi-Tanner, Yacki
    Polewski, Peter J.
    Gaddam, Mamatha
    Fisher, Nancy R.
    Kovacs, Attila J.
    Marinier, David E.
    JOURNAL OF GERIATRIC ONCOLOGY, 2022, 13 (07) : 1011 - 1016
  • [5] Factors associated with immune checkpoint inhibitor use among older adults with late-stage melanoma A population-based study
    Rai, Pragya
    Shen, Chan
    Kolodney, Joanna
    Kelly, Kimberly M.
    Scott, Virginia G.
    Sambamoorthi, Usha
    MEDICINE, 2021, 100 (07) : E24782
  • [6] The association between toxicity and efficacy of immune checkpoint inhibitors in older adults with NSCLC
    Rong, Yiran
    Ramachandran, Sujith
    Bhattacharya, Kaustuv
    Yang, Yi
    Earl, Sally
    Chang, Yunhee
    Bentley, John P.
    IMMUNOTHERAPY, 2024, 16 (16-17) : 1057 - 1068
  • [7] Neurological complications of immune checkpoint inhibitor cancer immunotherapy
    Zivelonghi, Cecilia
    Zekeridou, Anastasia
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2021, 424
  • [8] Arthritis risk with immune checkpoint inhibitor therapy for cancer
    Pundole, Xerxes
    Abdel-Wahab, Noha
    Suarez-Almazor, Maria E.
    CURRENT OPINION IN RHEUMATOLOGY, 2019, 31 (03) : 293 - 299
  • [9] Risk Factors of Venous Thromboembolic Disease in Cancer Patients Treated with Immune Checkpoint Inhibitor
    le Seve, Julien Denis
    Guedon, Alexis F.
    Bordenave, Stephanie
    Agard, Christian
    Connault, Jerome
    Pistorius, Marc-Antoine
    Quereux, Gaelle
    Espitia, Olivier
    THROMBOSIS AND HAEMOSTASIS, 2023, 123 (11) : 1049 - 1056
  • [10] Predictors of Toxicity Among Older Adults with Cancer
    Extermann, Martine
    Chetty, Indrin J.
    Brown, Stephen L.
    Al-Jumayli, Mohammed
    Movsas, Benjamin
    SEMINARS IN RADIATION ONCOLOGY, 2022, 32 (02) : 179 - 185